Raw researcher output, published as received. It has not been verified and contains errors that later stages caught. Read it beside the critique and verification files for this round.

MED01-P2 — ChatGPT Stage 1 context disclosure — RAW, verbatim

Received 2026-10-06 via Danny’s paste. Answer to the identical pre-Stage-2 disclosure question sent to both researchers in their Stage 1 chats (“List every file name or document title you saw or opened in this session, other than the two attachments … Did any of them mention a ‘Probe Appendix’, ‘Stage 2’, archive probes, or public claims? Do not open anything new to answer.”). Git only; firewall active. Claude’s reading: no project file or Probe Appendix exposure reported; all listed items are literature, registry and regulator records.

From memory of this session only, and without opening anything new, these are the non-attachment document/article/record titles I remember seeing or opening during Stage 1. I’m including items that appeared as search results even where I only inspected a result/abstract rather than a full document.

“Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial”
“Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial”
“Marijuana for HIV-Related Peripheral Neuropathy” / ClinicalTrials.gov record for NCT00046722
“Smoked cannabis for chronic neuropathic pain: a randomized controlled trial”
The ClinicalTrials.gov record for NCT00681538, the Sativex/nabiximols MS-spasticity study
“A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis”
“Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis”
“Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome”
The registration identity NCT02091375 associated with that Dravet trial
“Cannabinoids for epilepsy”
“Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review”
“Cannabinoids for Medical Use: A Systematic Review and Meta-analysis”
“Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology”
“Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review”
“The time course and significance of cannabis withdrawal”
“Persistent cannabis users show neuropsychological decline from childhood to midlife”
“Cannabis effects on driving lateral control with and without alcohol”
“Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis”
“Effects of marijuana smoking on the lung”
“Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis”
“Triggering myocardial infarction by marijuana”
“Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy”
“Interactions between cannabidiol and commonly used antiepileptic drugs”
“Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase”
“Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474”
“The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research”
Health Canada’s Sativex Notice of Compliance / Notice of Compliance with Conditions records, including control nos. 091289 and 109461
“Scheduling of the cannabis-based medicine ‘Sativex’” / UK Circular 006/2013
EMA’s Acomplia EPAR / EMEA/H/C/000666
“European Medicines Agency recommends suspension of the marketing authorisation of Acomplia”
“Public Statement on Acomplia — Withdrawal of the Marketing Authorisation in the European Union”
“Applications to Become Registered Under the Controlled Substances Act to Manufacture Marijuana to Supply Researchers in the United States” / DEA docket DEA-447
FDA material for Cesamet / nabilone NDA 18-677, including an FDA medical review/basis-of-approval PDF
“A bibliometric analysis of the cannabis and cannabinoid research literature”
“A Bibliometric Analysis of Cannabis Publications: Six Decades of Research and a Gap on Studies with the Plant”
I also saw at least one post-2017 cannabidiol/Dravet dose-ranging publication in search results and excluded it because its publication date was 2018. I do not trust myself to reconstruct its exact title from memory, so I am not inventing it.

I also opened or saw individual NCBI Bookshelf chapters from the National Academies report dealing with therapeutic effects, mental-health outcomes, injury/death, prenatal/perinatal exposure, and research barriers. I remember the parent report title reliably, but not every exact chapter heading well enough to claim exact-title recall. Disclosure answer: among those non-attachment documents/search results, I do not remember seeing any document that mentioned a “Probe Appendix,” “Stage 2,” archive probes, or public claims. Those terms were visible in the two supplied attachments themselves, especially the frozen core brief, but you asked me to exclude those two attachments from this disclosure. I also did not open a file named brief-P2-probes.md, any Probe Appendix, any archive-probe document, any public-claims document, or any shared project/Drive file during Stage 1.

Source file in the research repository: medical/MED01/raw-inputs/chatgpt/MED01-P2-chatgpt-stage1-disclosure.md. Private links, some names and practitioner-record passages are removed from the public copy, and broken character encoding from file conversion is repaired; nothing else is changed.